Caitong International Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Caitong International Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.16K	Buy	+197	New	+$5.54K	﹤0.01%	1125

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Caitong International Asset Management's RAPP Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 197 shares worth $6.16K. The stake represents ﹤0.01% of the portfolio and ranks #1125 among its holdings.

147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

Caitong International Asset Management held 197 shares of Rapport Therapeutics worth $6.16K as of Q1 2026.
Rapport Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Rapport Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1125 holding.
147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.